日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Long-term treatment of early Alzheimer's disease with donanemab

多那尼单抗用于早期阿尔茨海默病的长期治疗

Solfrizzi, Vincenzo; Imbimbo, Bruno P

Secretase inhibition in Alzheimer's disease therapeutics reveals functional roles of amyloid-beta42

阿尔茨海默病治疗中分泌酶抑制揭示了β-淀粉样蛋白42的功能作用

Daly, Timothy; Imbimbo, Bruno P

Tau Phosphorylation as an Adaptive Physiological Response: Implications for the Therapy of Tauopathies

Tau蛋白磷酸化作为一种适应性生理反应:对Tau蛋白病治疗的启示

Daly, Timothy; Imbimbo, Bruno P

Enhancing uptake of antidiabetic drugs to reduce cardiometabolic risk and dementia burden

提高抗糖尿病药物的服用率,以降低心血管代谢风险和痴呆负担。

Daly, Timothy; Imbimbo, Bruno P

Response to "Variability of cognitive changes after donanemab treatment"

对“多那奈单抗治疗后认知变化的变异性”的回应

Daly, Timothy; Kepp, Kasper P; Imbimbo, Bruno P

Long-term metformin use for Alzheimer's disease prevention?

长期服用二甲双胍可预防阿尔茨海默病吗?

Daly, Timothy; Imbimbo, Bruno P

Targeting dementia prevention with semaglutide: The case for APOE4 homozygotes

利用司美格鲁肽预防痴呆症:APOE4纯合子病例分析

Daly, Timothy; Imbimbo, Bruno P

ARTS as a cardiometabolic biomarker to bridge gaps in dementia diagnostics and therapeutics

ARTS作为一种心血管代谢生物标志物,可弥合痴呆症诊断和治疗方面的差距

Daly, Timothy; Imbimbo, Bruno P

Rethinking biological biomarkers to track treatment efficacy in Alzheimer's disease: Focus on brain connectivity

重新思考生物标志物在追踪阿尔茨海默病治疗效果中的应用:聚焦大脑连接

Pini, Lorenzo; Imbimbo, Bruno P

Association between amyloid-β42 levels and neuropsychiatric symptoms in Alzheimer's disease trials

阿尔茨海默病试验中淀粉样蛋白β42水平与神经精神症状之间的关联

Abanto, Jesus Thomas; Dwivedi, Alok K; Imbimbo, Bruno P; Espay, Alberto J